{"entity":{"id":"nct07218003","kind":"trial","name":"RNDO-564 alone or with pembrolizumab","aka":["A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4"],"tldr":"This early study tests RNDO-564 alone or with pembrolizumab in selected advanced tumors. It examines dose, side effects and early treatment activity.","summary":"This early study tests RNDO-564 alone or with pembrolizumab in selected advanced tumors. It examines dose, side effects and early treatment activity.\n\nInterventional study registered as NCT07218003, sponsored by Rondo Therapeutics. Registry phase: 1. Registry enrollment is 149 participants (estimated). Registry status checked October 10, 2026: enrolling by invitation. UCSF lists this study as closed to local enrollment; local availability and overall registry status are separate. See the registry for full eligibility and current sites.","status":"recruiting","asOf":"2026-10-10","links":[{"label":"ClinicalTrials.gov NCT07218003","url":"https://clinicaltrials.gov/study/NCT07218003"},{"label":"UCSF study listing and local availability","url":"https://clinicaltrials.ucsf.edu/trial/NCT07218003"}],"tags":["ucsf-breast-coverage","interventional"],"related":[],"cancers":["breast-cancer","tnbc"],"sections":[],"technologies":[],"targets":[],"drugs":["pembrolizumab"],"companies":[],"institutions":["ucsf"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07218003","phase":"1","setting":"Selected advanced solid tumors associated with Nectin-4","sponsor":"Rondo Therapeutics","participation":[{"nct":"NCT07218003","source":"https://clinicaltrials.gov/study/NCT07218003","fetchedAt":"2026-10-10T20:54:22.238412Z","studySha256":"30ad36ab807d71e3a7948723d1f847e14e86dd2890ac3907f5a38a2b51e17ce3","overallStatus":"ENROLLING_BY_INVITATION","lastUpdatePosted":"2026-06-11","leadSponsor":"Rondo Therapeutics","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":149,"enrolmentType":"ESTIMATED","siteCount":11,"recruitingSiteCount":0,"countries":["United States"]}],"started":"2025-11-17","startedType":"actual","enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07218003/","neighbours":{"cancer":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"institution":[{"id":"ucsf","kind":"institution","name":"UCSF Helen Diller Family Comprehensive Cancer Center","route":"/institutions/ucsf/"}]}}